Last reviewed · How we verify
Synergy for Bacterial Meningitis
Approved treatments
- Ramycin
Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins. - Garamycin · Merck & Co.
- Tobi · Novartis
- Vantobra · Pfizer
- Gentamicin · Merck & Co.
- Nebcin · University Hospital, Lille
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Synergy for Bacterial Meningitis patent landscape — cliff calendar, originator estates, attackable patents
- Synergy for Bacterial Meningitis treatment landscape brief
- Synergy for Bacterial Meningitis treatment updates RSS
Frequently asked questions about Synergy for Bacterial Meningitis
What drugs treat Synergy for Bacterial Meningitis?
Tracked treatments include Ramycin, Garamycin, Tobi, Vantobra, Gentamicin, Nebcin.
What is the treatment for Synergy for Bacterial Meningitis?
Standard treatment for Synergy for Bacterial Meningitis includes Ramycin, Garamycin, Tobi, Vantobra, Gentamicin. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Synergy for Bacterial Meningitis patent cliff · Synergy for Bacterial Meningitis CI report
- Treatment: Ramycin
- Treatment: Garamycin · Merck & Co.
- Treatment: Tobi · Novartis
- Treatment: Vantobra · Pfizer
- Treatment: Gentamicin · Merck & Co.
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing